{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T12:18:32Z","timestamp":1775045912153,"version":"3.50.1"},"reference-count":26,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T00:00:00Z","timestamp":1646265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Impaired glucose tolerance (IGT) is a common carbohydrate metabolism disorder world-wide. To evaluate the efficacy and safety of 12-week Subetta therapy in correcting 2-h plasma glucose in patients with IGT, a multicenter, double-blind, placebo-controlled, randomized clinical trial was performed. Derived by technological treatment of antibodies to insulin receptor \u03b2-subunit and endothelial NO synthase, Subetta increases the sensitivity of insulin receptors by activating the insulin signaling pathway. Oral glucose tolerance test (OGTT), fasting plasma glucose (FPG), and glycated hemoglobin (HbA1c) were examined at screening, after 4 and 12 weeks. In Per Protocol population, 2-h plasma glucose in the Subetta group decreased by 2.05 \u00b1 2.11 mmol\/L (versus 0.56 \u00b1 2.55 mmol\/L in the Placebo group) after 12 weeks. The difference between the two groups was 1.49 \u00b1 2.33 mmol\/L (p &lt; 0.0001). After 12 weeks, 65.2% of patients had 2-h plasma glucose &lt;7.8 mmol\/L. FPG remained almost unchanged. HbA1c tended to decrease. The number of adverse events did not differ in both groups. Subetta treatment is beneficial for patients with IGT; it also prevents progression of carbohydrate metabolism disorders.<\/jats:p>","DOI":"10.3390\/jcm11051390","type":"journal-article","created":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T09:24:53Z","timestamp":1646299493000},"page":"1390","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["A New Approach to Overcome Insulin Resistance in Patients with Impaired Glucose Tolerance: The Results of a Multicenter, Double-Blind, Placebo-Controlled, Randomized Clinical Trial of Efficacy and Safety of Subetta"],"prefix":"10.3390","volume":"11","author":[{"given":"Ashot","family":"Mkrtumyan","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Moscow Clinical Scientific and Practical Center Named after A. S. Loginov, 111123 Moscow, Russia"},{"name":"Department of Endocrinology and Diabetology, A. I. Evdokimov Moscow State University of Medicine and Dentistry, 127473 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Ametov","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Faculty of Medicine, Medical Academy of Continuing Professional Education, 125993 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatiana","family":"Demidova","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, City Clinical Hospital Named after V. P. Demikhova, 117463 Moscow, Russia"},{"name":"Department of Endocrinology, Faculty of Medicine, Pirogov Russian National Research Medical University, 117997 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Volkova","sequence":"additional","affiliation":[{"name":"Department of Faculty Therapy, Faculty of Medicine, Pavlov First Saint Petersburg State Medical University, 197022 St. Petersburg, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ekaterina","family":"Dudinskaya","sequence":"additional","affiliation":[{"name":"Department of Age-Related Metabolic and Endocrine Disorders, Russian Gerontological Research and Clinical Center, Pirogov Russian National Research Medical University, 129226 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arkady","family":"Vertkin","sequence":"additional","affiliation":[{"name":"Department of Therapy, Clinical Pharmacology and Emergency Medicine, A. I. Evdokimov Moscow State University of Medicine and Dentistry, 127473 Moscow, Russia"},{"name":"Department of Therapy, City Clinical Hospital Named after S.I. Spasokukotsky, 127006 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergei","family":"Vorobiev","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Rostov State Medical University, 344022 Rostov-on-Don, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,3,3]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2006). Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycemia, World Health Organization. Available online: https:\/\/www.who.int\/diabetes\/publications\/diagnosis_diabetes2006\/en\/."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"American Diabetes Association (2021). Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2021. Diabetes Care, 44, S15\u2013S33.","DOI":"10.2337\/dc21-S002"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S2213-8587(19)30093-2","article-title":"Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance: 30-year results of the Da Qing Diabetes Prevention Outcome Study","volume":"7","author":"Gong","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_4","unstructured":"(2021). International Diabetes Federation: IDF Diabetes Atlas, International Diabetes Federation. [10th ed.]. Available online: https:\/\/www.diabetesatlas.org\/en\/."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Yip, W.C.Y., Sequeira, I.R., Plank, L.D., and Poppitt, S.D. (2017). Prevalence of Pre-Diabetes across Ethnicities: A Review of Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT) for Classification of Dysglycaemia. Nutrients, 9.","DOI":"10.3390\/nu9111273"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"107843","DOI":"10.1016\/j.diabres.2019.107843","article-title":"Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th ed","volume":"157","author":"Saeedi","year":"2019","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s40842-019-0080-0","article-title":"Global epidemiology of prediabetes\u2014present and future perspectives","volume":"5","author":"Hostalek","year":"2019","journal-title":"Clin. Diabetes Endocrinol."},{"key":"ref_8","unstructured":"idf.org (2022, January 13). International Diabetes Federation; c2021. Available online: https:\/\/idf.org\/InternationalDiabetesFederation."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"9453","DOI":"10.3390\/nu7115475","article-title":"The subtle balance between lipolysis and lipogenesis: A critical point in metabolic homeostasis","volume":"7","author":"Saponaro","year":"2015","journal-title":"Nutrients"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Diabetes Prevention Program Research Group (2015). Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: The Diabetes Prevention Program Outcomes Study. Lancet Diabetes Endocrinol., 3, 866\u2013875.","DOI":"10.1016\/S2213-8587(15)00291-0"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e013806","DOI":"10.1136\/bmjopen-2016-013806","article-title":"Clinical impact of lifestyle interventions for the prevention of diabetes: An overview of systematic reviews","volume":"6","author":"Howells","year":"2016","journal-title":"BMJ Open"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"American Diabetes Association (2021). Prevention or Delay of Type 2 Diabetes: Standards of Medical Care in Diabetes-2021. Diabetes Care, 44, S34\u2013S39.","DOI":"10.2337\/dc21-S003"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1056\/NEJMoa0908359","article-title":"Glycated Hemoglobin, Diabetes, and Cardiovascular Risk in Nondiabetic Adults","volume":"362","author":"Selvin","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_14","first-page":"393","article-title":"Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance: 30-year results of the Da Qing Diabetes Prevention Outcome Study Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","volume":"346","author":"Knowler","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.4239\/wjd.v6.i12.1207","article-title":"Treatment of prediabetes","volume":"6","author":"Kanat","year":"2015","journal-title":"World J. Diabetes"},{"key":"ref_16","unstructured":"European Medicines Agency (2021, December 07). Saxenda. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/saxenda."},{"key":"ref_17","unstructured":"European Medicines Agency (2021, December 07). Wegovy. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/summaries-opinion\/wegovy."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e169","DOI":"10.1038\/nutd.2015.20","article-title":"Subetta increases phosphorylation of insulin receptor \u03b2-subunit alone and in the presence of insulin","volume":"5","author":"Gorbunov","year":"2015","journal-title":"Nutr. Diabetes"},{"key":"ref_19","first-page":"12","article-title":"Subetta\u2014A new activator of the insulin receptor","volume":"15","author":"Mkrtumyan","year":"2019","journal-title":"Eff. Pharmacother."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s10517-015-2992-8","article-title":"Subetta Enhances Sensitivity of Human Muscle Cells to Insulin","volume":"159","author":"Gorbunov","year":"2015","journal-title":"Bull. Exp. Biol. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.diabres.2018.04.044","article-title":"Efficacy and safety of Subetta add-on therapy in type 1 diabetes mellitus: The results of a multicenter, double-blind, placebo-controlled, randomized clinical trial","volume":"142","author":"Mkrtumyan","year":"2018","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_22","unstructured":"Clinicaltrials.gov (2021, December 07). Clinical Trial of Efficacy and Safety of Subetta in the Treatment of Impaired Glucose Tolerance, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03725033?term=Subetta&draw=2&rank=3."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2307\/2530245","article-title":"A multiple testing procedure for clinical trials","volume":"35","author":"Fleming","year":"1979","journal-title":"Biometrics"},{"key":"ref_24","unstructured":"Santaguida, P.L., Balion, C., Hunt, D., Morrison, K., Gerstein, H., Raina, P., Booker, L., and Yazdi, H. (2005). Diagnosis, Prognosis, and Treatment of Impaired Glucose Tolerance and Impaired Fasting Glucose, Agency for Healthcare Research and Quality. Evidence Report\/Technology Assessment No. 128. (Prepared by the McMaster University Evidence-based Practice Center under Contract No. 290-02-0020). AHRQ Pub. No 05-E026-2."},{"key":"ref_25","unstructured":"(2018). Guideline on Clinical Investigation of Medicinal Products in the Treatment or Prevention of Diabetes Mellitus, European Medicines Agency. CPMP\/EWP\/1080\/00 Rev. 2 Committee for Medicinal Products for Human Use (CHMP)."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"4030","DOI":"10.2337\/db13-0627","article-title":"Nitric oxide directly promotes vascular endothelial insulin transport","volume":"62","author":"Wang","year":"2013","journal-title":"Diabetes"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/5\/1390\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:31:17Z","timestamp":1760135477000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/5\/1390"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,3]]},"references-count":26,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,3]]}},"alternative-id":["jcm11051390"],"URL":"https:\/\/doi.org\/10.3390\/jcm11051390","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,3]]}}}